Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Egle

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
Breast (Edinburgh, Scotland)|February 22, 2025
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trialsKerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Breast (Edinburgh, Scotland)|March 4, 2022
A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohortAparna Gunda, Chetana Basavaraj, Chandra Prakash Serkad V, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8Martin Filipits, Margaretha Rudas, Verena Kainz, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)Michael Knauer, Daniel Egle, Stefanie Hayoz, et al.
The Lancet. Oncology|February 24, 2019
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trialMichael Gnant, Georg Pfeiler, Günther G Steger, et al.
Anticancer Research|June 26, 2024
Extracellular Vesicle DNA Extraction and Sequencing in Ancient Serum Samples From Patients With Breast CancerMartin Heidinger, Daniel Egle, Salvatore Piscuoglio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast CancerChristian F Singer, Yen Y Tan, Florian Fitzal, et al.
NPJ Breast Cancer|April 8, 2026
Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 TrialDaniel Egle, Dominik Hlauschek, Simon Peter Gampenrieder, et al.
Breast (Edinburgh, Scotland)|November 6, 2025
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34Stephanie Kacerovsky-Strobl, Christine Deutschmann, Dominik Hlauschek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2024
Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective StudyChristine Brunner, Marjan Arvandi, Christian Marth, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Breast (Edinburgh, Scotland)|February 22, 2025
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trialsKerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Breast (Edinburgh, Scotland)|March 4, 2022
A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohortAparna Gunda, Chetana Basavaraj, Chandra Prakash Serkad V, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8Martin Filipits, Margaretha Rudas, Verena Kainz, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)Michael Knauer, Daniel Egle, Stefanie Hayoz, et al.
The Lancet. Oncology|February 24, 2019
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trialMichael Gnant, Georg Pfeiler, Günther G Steger, et al.
Anticancer Research|June 26, 2024
Extracellular Vesicle DNA Extraction and Sequencing in Ancient Serum Samples From Patients With Breast CancerMartin Heidinger, Daniel Egle, Salvatore Piscuoglio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast CancerChristian F Singer, Yen Y Tan, Florian Fitzal, et al.
NPJ Breast Cancer|April 8, 2026
Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 TrialDaniel Egle, Dominik Hlauschek, Simon Peter Gampenrieder, et al.
Breast (Edinburgh, Scotland)|November 6, 2025
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34Stephanie Kacerovsky-Strobl, Christine Deutschmann, Dominik Hlauschek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2024
Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective StudyChristine Brunner, Marjan Arvandi, Christian Marth, et al.
Pageof 9